The FDA has delayed its decision on Parsippany, NJ-based Pacira Pharmaceuticals’ drug—a long-acting version of the pain drug bupivacaine called Exparel—according to a press release. Pacira, which also has operations in San Diego, went public in February, and investors pushed the company’s stock up more than 47 percent in anticipation of a July decision from the FDA. Pacira is now expecting a ruling by October 28. The company’s shares fell 14 percent to $11.30 in pre-market trading.
Author: Arlene Weintraub
Arlene is an award-winning journalist specializing in life sciences and technology. She was previously a senior health writer based out of the New York City headquarters of BusinessWeek, where she wrote hundreds of articles that explored both the science and business of health. Her freelance pieces have been published in USA Today, US News & World Report, Technology Review, and other media outlets. Arlene has won awards from the New York Press Club, the Association of Health Care Journalists, the Foundation for Biomedical Research, and the American Society of Business Publication Editors. Her book about the anti-aging industry, Selling the Fountain of Youth, was published by Basic Books in September 2010.
View all posts by Arlene Weintraub
